Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 10/20 | 0.77 |
| ▸ | CCR2 | P41597 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344257 | 0.90 | CCR9 (0.75) | CCR9CCR2LMNAHTTMAPT | |
| SCHEMBL27979 | 0.89 | LMNA (0.83) | CCR9CCR2LMNAHTTMAPT | |
| SCHEMBL28006 | 0.88 | LMNA (0.86) | CCR9CCR2LMNAHTTMAPT | |
| Vercirnon SCHEMBL342225 | 0.87 | CCR9 (1.00) | CCR9CCR2LMNAHTTMAPT | |
| Vercirnon SCHEMBL15766988 | 0.86 | CCR9 (0.98) | CCR9CCR2LMNAHTTMAPT | |
| SCHEMBL10251868 | 0.85 | BDKRB1 (0.62) | CCR9CCR2LMNAHTTKMT2A | |
| SCHEMBL28518 | 0.84 | LMNA (0.80) | CCR9CCR2LMNAHTTMAPT | |
| SCHEMBL12242366 | 0.84 | LMNA (0.80) | CCR9LMNAHTTMAPTTP53 | |
| SCHEMBL13137558 | 0.84 | LMNA (0.80) | CCR9CCR2LMNAHTTMAPT | |
| SCHEMBL27666 | 0.84 | CCR9 (0.75) | CCR9CCR2LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8815887-B2 | Prophylactic or therapeutic method for Sjogren's syndrome | MILLENIUM PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2014088113-A1 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME USING SPECIFIC CCR9 RECEPTOR INHIBITORS/ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140155437-A1 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155437-A1 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME | SSB, SCLY, HLA-DRB1 | CCR9 1218/4885CCR2 1700/4885LMNA 3957/4885 |
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885LMNA 4484/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885LMNA 4484/4885 |
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885LMNA 4484/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885LMNA 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.